Stowers Institute Lays Ambitious Plans for K.C.

Let's say you want to build the best biomedical research facility, bar none. The catch is, it will be in Kansas City. Can you still hope to lure top scientists away from their prestigious postings in world capitals to an untested center in Missouri? Philanthropists Virginia Stowers and James Stowers Jr. think so. And they have a plan to make it happen. On 10 acres across the street from the University of Missouri, the foundations already are being laid for their six-story, 594,000-square-foot

Written bySteve Bunk
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Let's say you want to build the best biomedical research facility, bar none. The catch is, it will be in Kansas City. Can you still hope to lure top scientists away from their prestigious postings in world capitals to an untested center in Missouri? Philanthropists Virginia Stowers and James Stowers Jr. think so. And they have a plan to make it happen.

On 10 acres across the street from the University of Missouri, the foundations already are being laid for their six-story, 594,000-square-foot Stowers Institute for Medical Research, the first phase of which will open in the year 2000. Construction is being financed by $125 million in tax-free municipal bonds. That expenditure alone won't fill the site with quality researchers, but what could do the trick is the institute's $335 million endowment, intended to eventually provide about 600 scientists with freedom from the necessity to compete for research grants.

The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies